UNIGE document Scientific Article
previous document  unige:31879  next document
add to browser collection
Title

Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis

Authors
Kossovsky, Michel P
Keller, Pierre-Frederic
Published in Swiss Medical Weekly. 2012, vol. 142, p. w13536
Abstract Anticoagulation therapy is routinely used in cases of non ST-segment elevation acute coronary syndromes (NSTE-ACS). The most commonly used drug in such events is enoxaparin, a low molecular weight heparin. Fondaparinux, a synthetic pentasaccharide, is as effective as enoxaparin in terms of survival or residual angina pectoris and significantly reduces bleeding complications. The purpose of this study was to assess the magnitude of cost reductions if enoxaparin were replaced by fondaparinux in Switzerland.
Keywords Acute Coronary Syndrome/drug therapy/economicsAgedAnticoagulants/economics/therapeutic useCosts and Cost AnalysisDrug Costs/statistics & numerical dataEnoxaparin/economics/therapeutic useFactor XFemaleFollow-Up StudiesHospital Costs/statistics & numerical dataHumansLength of Stay/economicsMalePolysaccharides/economics/therapeutic useRetrospective StudiesSwitzerlandTreatment Outcome
Identifiers
PMID: 22430741
Full text
Article (Published version) (418 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Groupe Jean-Michel Gaspoz (23)
Citation
(ISO format)
KOSSOVSKY, Michel P et al. Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis. In: Swiss Medical Weekly, 2012, vol. 142, p. w13536. https://archive-ouverte.unige.ch/unige:31879

123 hits

1 download

Update

Deposited on : 2013-12-09

Export document
Format :
Citation style :